NZOZ „Pro Cordis” Sopockie Centrum Badań Kardiologicznych Paweł Miękus

The medical center is at the forefront of cardiology research, particularly focusing on Heart Failure with Reduced Ejection Fraction (HFrEF). This condition is characterized by the heart's inability to pump blood efficiently, leading to various health complications.

• Innovative therapeutic approaches for HFrEF
• Safety and tolerability assessments of new treatments
• Pharmacokinetics of emerging heart failure medications

Through rigorous clinical trials, the center is pioneering advancements in the treatment of HFrEF, enhancing patient outcomes and quality of life.

Specializing in the management of Atrial Fibrillation, the center conducts extensive research to improve therapeutic strategies for this common heart rhythm disorder. Atrial Fibrillation can lead to serious complications such as stroke and heart failure.

• Comparative studies of anticoagulant therapies
• Evaluation of bleeding risks associated with treatment
• Development of safer and more effective anticoagulants

The center's research efforts are crucial in refining treatment protocols, minimizing risks, and enhancing the safety profile of anticoagulant medications for patients with Atrial Fibrillation.